The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Solasia Pharma
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Jun Watanabe
Speakers' Bureau - Covidien; Johnson & Johnson/Janssen; Lilly Japan
Research Funding - Medtronic (Inst)
 
Kohei Shitara
Honoraria - Bristol-Myers Squibb; Janssen; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Guardant Health; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hisatsugu Ohori
No Relationships to Disclose
 
Manabu Shiozawa
Speakers' Bureau - Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hirofumi Yasui
No Relationships to Disclose
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Takeo Sato
Consulting or Advisory Role - Takeda
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Yakuhin; Taiho Oncology; Takeda
 
Takeshi Naito
Honoraria - Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kaken Pharmaceutical; Lilly Japan; Merck; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Taiho Pharmaceutical (Inst)
 
Yoshito Komatsu
Speakers' Bureau - Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
Research Funding - Chugai Pharma
 
Junpei Soeda
Employment - Takeda
 
Kouji Yamamoto
Honoraria - Chugai Pharma; CM Plus; CMIC Co., Ltd.; J-Pharma; Johokiko; Sysmex; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Kyowa Kirin International (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Riu Yamashita
Consulting or Advisory Role - Takeda
 
Kiwamu Akagi
Honoraria - AstraZeneca; Chugai Pharma; Mochida Pharmaceutical Co. Ltd.; MSD; Roche Molecular Diagnostics; Taiho Pharmaceutical; Takeda
 
Atsushi Ochiai
No Relationships to Disclose
 
Hiroyuki Uetake
Speakers' Bureau - Chugai Pharma; Takeda
 
Katsuya Tsuchihara
Honoraria - Bayer Yakuhin; Boehringer Ingelheim Seiyaku; Chugai Pharma; Eisai; Gilead Sciences; Illumina; Takeda
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)